885232-47-3

Upstream product

• 2105-61-5 1,2,4-trifluoro-5-nitrobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 885232-48-4 4-[5-(4-chloro-benzylamino)-2-fluoro-4-nitro-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 885232-44-0 4-[2-fluoro-4-nitro-5-(4-trifluoromethoxy-benzylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 1353898-62-0 N-[2-(2-{2,5-difluoro-4-[4-((S)-2-hydroxypropyl)piperazin-1-yl]phenylamino}pyrrolo[2,1-f][1,2,4]triazin-7-yl)phenyl]-N-methylmethanesulfonamide trifluoroacetic acid 
• 1233185-03-9 C₂HF₃O₂*C₁₀H₁₁F₂N₃O₂ 

Relevant academic research and scientific papers

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to 1,3,4-oxadiazole derivative compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutical composition comprising the same, a therapeutic method using the composition, and a method for preparing the same, and the 1,3,4-oxadiazole derivative compounds are represented by a following chemical formula (I).

Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f ][1,2,4]triazines: Identification of orally bioavailable, efficacious ALK inhibitors

Chemical strategies to mitigate cytochrome P450-mediated bioactivation of novel 2,7-disubstituted pyrrolo[2,1-f][1,2,4]triazine ALK inhibitors are described along with synthesis and biological activity. Piperidine-derived analogues showing minimal microsomal reactive metabolite formation were discovered. Potent, selective, and metabolically stable ALK inhibitors from this class were identified, and an orally bioavailable compound (32) with antitumor efficacy in ALK-driven xenografts in mouse models was extensively characterized.

New indole or benzimidazole derivatives as CB1 inverse agonists

Provided are compounds of the formula I: and pharmaceutically acceptable salts thereof, processes for making said compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compound and pharmaceutically acceptable